Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Shares Outstanding (Weighted Average) (2016 - 2025)

Ocular Therapeutix has reported Shares Outstanding (Weighted Average) over the past 13 years, most recently at $187.2 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $187.2 million for Q4 2025, up 18.31% from a year ago — trailing twelve months through Dec 2025 was $187.2 million (up 18.31% YoY), and the annual figure for FY2025 was $187.2 million, up 18.31%.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $187.2 million at Ocular Therapeutix, up from $183.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for OCUL hit a ceiling of $187.2 million in Q4 2025 and a floor of $76.1 million in Q1 2021.
  • Median Shares Outstanding (Weighted Average) over the past 5 years was $78.2 million (2023), compared with a mean of $112.4 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 0.56% in 2022 and later soared 112.47% in 2024.
  • Ocular Therapeutix's Shares Outstanding (Weighted Average) stood at $76.4 million in 2021, then increased by 0.63% to $76.9 million in 2022, then grew by 3.84% to $79.8 million in 2023, then skyrocketed by 98.26% to $158.3 million in 2024, then increased by 18.31% to $187.2 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $187.2 million (Q4 2025), $183.9 million (Q3 2025), and $171.0 million (Q2 2025) per Business Quant data.